- Guide to PHARMACOLOGY
Synonyms: Cibinqo® | compound 25 [PMID: 29298069] | PF-04965842 | PF04965842
abrocitinib is an approved drug (UK, Japan & EMA (2021), FDA (2022))
Compound class: Synthetic organic
Comment: Abrocitinib (PF-04965842) is a JAK inhibitor . X-ray crystal structures of PF-04965842 bound to both JAK1 and JAK2 have been deposited with the Protein DataBank (accession IDs 6BBU and 6BBV respectively). We used the SMILES string supplied with the article in which the structure was declared  to generate our representation of the chemical structure. The IUPAC name in abrocitinib's INN record resolves to the same StdInChIKey as our structure. PubChem CID 78323835 represents the structure without specified stereochemistry.
The JAKs are immunokinases that are molecular targets of therapeutics which are used in the treatment of immune-mediated diseases.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Abrocitinib (PF-04965842) was advanced to clinical trials for autoimmune conditions, and reached Phase 3 evaluation for atopic dermatitis and Phase 2 for plaque psoriasis (NCT02201524). Results from the psoriasis trial have been published , and these indicated that PF-04965842 improved disease symptoms and was well tolerated in patients with moderate to severe psoriasis. Further development for psoriasis has been terminated by the sponsor (Pfizer) for business reasons. Development in moderate to severe atopic dermatitis is continuing in Pfizer's JAK1 Atopic Dermatitis Efficacy and Safety (JADE) program, which incluides the JADE MONO-1 (NCT03349060) and JADE MONO-2 (NCT03575871) trials. Results demonstrating significant efficacy in the JADE MONO-1 study were published in July 2020 , and similarly supportive results from JADE MONO-2 followed in August 2020 .
Abrocitinib was first approved for clinical use in 2021. Under these authorisations it is indicated as a treatment for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The FDA's approval as a treatment for atopic dermatitis was granted in January 2022.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02201524||Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis||Phase 2 Interventional||Pfizer|
|NCT03575871||Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis||Phase 3 Interventional||Pfizer|
|NCT03349060||Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis||Phase 3 Interventional||Pfizer||This RCT is known as the 'JADE MONO-1' trial. Results published in 2020, indicated that once daily, oral abrocitinib for 12 weeks was effective and well tolerated in trial participants with moderate-to-severe atopic dermatitis.||3|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)